Monthly Archives - December 2020

Cognoptix Announces Formation of a New Board of Directors

Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer's disease (AD). As another milestone of the Series R restart, recapitalization, and revitalization, the company named a new Board of Directors (BOD) formed under the leadership of Dr. Susanne Wilke, Ph.D., Cognoptix' new President and CEO. Read more >>
Read more...

Groton Connecticut based Astrocyte Pharmaceuticals is raising $8,655,148.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Astrocyte Pharmaceuticals is raising $8,655,148.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Korinek played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. Read more >>
Read more...

ZetrOZ Systems’ Wearable Ultrasound Device, SAM, Receives Expanded FDA Re-Approval, Positioning the Company for Market Growth in 2021

ZetrOZ Systems, developers of the Sustained Acoustic Medicine (SAM) wearable ultrasound, an FDA-cleared bio regenerative medical device, is the global leader in development of SAM technologies. With its reapproval for expanded use in 2020, the use of SAM ultrasound technology in both professional and at-home applications is expected to increase market growth significantly over the next several years. Read more >>
Read more...

Teenager Gets Gift of Sight

When Jimy Rubio came to tour the SEA LIFE and Legoland Discovery Center in Grapevine, he didn't know he would leave with a life-changing gift. Jimy Rubio toured the SEA LIFE and Legoland Discovery Center on Monday with the help of a device called eSight 4, allowing him to see things he's never been able to see on his own. Read more >>
Read more...

Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model

Hoth has a partnership agreement with Zylö Therapeutics Inc., to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Read more >>
Read more...